Acquired resistance in NSCLC: the journey from clinical definition to molecular understanding
- PMID: 34610278
- DOI: 10.1016/j.annonc.2021.09.018
Acquired resistance in NSCLC: the journey from clinical definition to molecular understanding
Conflict of interest statement
Disclosure EW: AstraZeneca, research grant, institutional; BMS, advisory board, institutional; Boehringer Ingelheim, advisory board, institutional; MSD, advisory board, institutional; JV: AstraZeneca, advisory board, institutional; AstraZeneca, invited speaker, institutional; BMS, advisory board, institutional; BMS, invited speaker, institutional; Boehringer Ingelheim, advisory board, institutional; Daichi Sankyo, advisory board, institutional; MSD, advisory board, institutional; MSD, invited speaker, institutional; Novartis, invited speaker, institutional; Pfizer, advisory board, institutional; Roche, advisory board, institutional; MSD, research grant, institutional, no financial interest.
Comment on
-
Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer.Ann Oncol. 2021 Dec;32(12):1597-1607. doi: 10.1016/j.annonc.2021.08.2151. Epub 2021 Sep 3. Ann Oncol. 2021. PMID: 34487855 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical